Brief: AIM Vaccine Says Second Generation Of Absorbed Tetanus Vaccine Obtained Clinical Trial Approval
19/12/2024 15:20
Dec 19 (Reuters) - AIM Vaccine Co Ltd 6660.HK :
* SECOND GENERATION OF HIGHLY-EFFECTIVE ABSORBED TETANUS
VACCINE
OBTAINED CLINICAL TRIAL APPROVAL FROM NMPA
Further company coverage: 6660.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM Vaccine
See all newsBrief: AIM Vaccine Co Submits Application For Human Diploid Cell Rabies Vaccine In China
Brief: AIM Vaccine Says Tibet Bohai To Subscribe 37.4 Million Shares At RMB1.07 Each
Brief: AIM Vaccine Approves Issuance Of Up To 40 Million Domestic Shares
Brief: Aim Vaccine Says Serum-Free Rabies Vaccine Passes Inspection
Brief: AIM Vaccine Updates On 20-Valent Pneumococcal Polysaccharide Conjugate Vaccine